AstraZeneca receives approval to import and distribute Eculizumab

AstraZeneca Pharma India Limited has announced that it has received regulatory approval to import and distribute Eculizumab concentrate for solution (300 mg, 10mg/ml) under the brand name SOLIRIS. This approval was granted by the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India.

Eculizumab is indicated for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS), targeting complement-mediated thrombotic microangiopathy. With this approval, AstraZeneca is set to introduce this therapeutic solution in India, subject to additional statutory approvals if required.

This marks a significant step towards offering advanced treatment options for patients with these rare and severe disorders in the country.

The shares of AstraZeneca closed 0.76% higher at Rs 6782.95 on BSE. 

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.